KYMR

Over the past six months, Kymera's stock has been influenced by several events. The company announced strong Q2 2026 financial results on August 5, 2026, reporting a loss of $0.62 per share (beating estimates) and revenue of $65 million (exceeding estimates and representing a 465.2% year-over-year increase), which positively impacted the stock. Enrollment for the KT-621 BROADEN2 Phase 2b atopic dermatitis trial was completed nearly six months ahead of schedule by September 1, 2026, with topline data expected by year-end 2026 and Phase 3 trials by mid-2027, contributing to positive market sentiment. On October 8, 2026, Raymond James initiated coverage with an "Outperform" rating and a $140 price target, while other firms like Citi, B.Riley, Piper Sandler, and Goldman Sachs also provided positive updates and price target increases. Insider stock sales occurred on October 1, 2026, and September 4, 2026, with CEO Nello Mainolfi notifying an intention to sell 30,000 shares and Brian Adams selling 6,371 shares, which can be viewed cautiously by investors. Overall, the stock price increased by 82.69% to 84.2% over the last 12 months, with a year-to-date return of 35.12%, though it decreased by 10.44% to 9.7% in the month leading up to October 6, 2026.